NCT02946684 (RIOT-A) is a Phase 2, PHASE3 clinical trial of Letrozole in Infertility, sponsored by Sven O. Skouby.

Who is sponsoring NCT02946684?

NCT02946684 is sponsored by Sven O. Skouby.

What drugs are being tested in NCT02946684?

Interventions in NCT02946684: Letrozole, Placebo.

What condition does NCT02946684 study?

NCT02946684 studies Infertility.

Is NCT02946684 still recruiting?

NCT02946684 is currently completed. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT02946684: RIOT-A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

Completed Phase 2, PHASE3 Last updated 8 July 2019

What this trial tests

Phase 2, PHASE3 trial testing Letrozole in Infertility in 129 participants. Completed in 30 October 2018.

Timeline

1 February 2017

Primary endpoint
30 October 2018

30 October 2018

Quick facts

Lead sponsor	Sven O. Skouby
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	129
Start date	1 February 2017
Primary completion	30 October 2018
Estimated completion	30 October 2018
Sites	4 locations across Denmark

Drugs / interventions tested

Letrozole — full drug profile →
Placebo

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

Sven O. Skouby

Who can join

Adults 18 to 40, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project seeks to determine whether estradiol suppression achieved with adjuvant treatment with an aromatase inhibitor improves end-follicular and midluteal phase parameters during IVF. 128 patients will be randomized to either placebo or active treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
Bülow NS, Skouby SO, Warzecha AK, Udengaard H, et al · · 2022 · cited 26× · PMID 34792133 · DOI 10.1093/humrep/deab249
Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
Bülow NS, Warzecha AK, Nielsen MV, Andersen CY, et al · · 2023 · cited 9× · PMID 37699851 · DOI 10.1093/humrep/dead182

Verify or expand the search:

Other trials of Letrozole

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07570966 — Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · not yet recruiting
NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06905301 — Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and W · recruiting
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02946684 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sven O. Skouby
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02946684.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing